AtriCure (ATRC) Tops Q4 EPS by 16c, provides guidance

AtriCure (NASDAQ: ATRC) reported Q4 EPS of $0.06, $0.16 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $140.5 million versus the consensus estimate of $139.55 million.

GUIDANCE:

AtriCure sees FY2026 EPS of $0.09-$0.15, versus the consensus of ($0.03). AtriCure sees FY2026 revenue of $600-610 million, versus the consensus of $602 million.

For earnings history and earnings-related data on AtriCure (ATRC) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• EyePoint Inc. (EYPT) PT Lowered to $8 at Jefferies
• B.Riley Downgrades Lantheus Holdings (LNTH) to Neutral